| Budget Amount *help |
¥42,380,000 (Direct Cost: ¥32,600,000、Indirect Cost: ¥9,780,000)
Fiscal Year 2019: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2018: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2017: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2016: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2015: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
|
|---|
| Outline of Final Research Achievements |
To produce allogenic ICM injected chimeric marmoset embryos, efficient processing method of ICM has been examined and contributions of the donor ICM cells into the host ICM have been observed by live cell imaging technic.
OCT4 distal enhancer is known as a marker for human naive pluripotent stem cells. Therefore marmoset ES cells with reporter gene at homologous region to human OCT4 distal enhancer in marmoset were established. Using this ES cell line, marmoset primed ES cells were converted morphologically similar to human naive pluripotent stem cells. To analyze kinetics of chimeric marmoset embryos, a pseudo post-implantation embryo culture method that allows in vitro observation of post-implantation embryo development has been developed. Finally, using allogenic ICM transplanted chimeric embryo production method, marmoset naive ES cells were injected into marmoset host embryos and kinetics of the naive ES cells in the embryo was analyzed by pseudo post-implantation embryo culture.
|
